Solitary plasmacytoma is localized plasma-cell cancer, distinct from systemic multiple myeloma. European panel 2018.
Confidence: moderate. Independent comparative benefits remain unestablished.
- One visible mass does not complete staging. NCI professional PDQ.
- Bone and primary extraosseous disease need distinct assessment. NCI patient PDQ.
- Radiotherapy is central. 2026 IMWG.
- Sudden neurological loss or severe breathing difficulty is an emergency. NHS neurological warnings; NHS breathing warnings.
Table of contents
- Evidence summary
- Forms
- Work-up
- Local treatment
- Support, fatigue and complementary products
- Systemic treatment
- Risks and urgent assessment
- Medicines, dental care and other coordination
- Pregnancy and fertility planning
- Follow-up
- Animal and laboratory evidence
- Funding and source roles
- Frequently asked questions
- Sources and funding notes
Evidence summary
Clinical descriptions, care guidance and independently established treatment outcomes have different evidentiary roles. The table identifies what the reviewed sources can support and which financial or clinical questions remain unresolved.
| Question / approach | Evidence reviewed | Funding / conflicts | Interpretation / limits |
|---|---|---|---|
| Bone/soft-tissue identity | NCI PDQ | Lead/board financial chain below | Descriptive context; systemic myeloma separate. |
| Local radiotherapy | 2026 IMWG | IMF/author ties | Framework, no independent effect size. |
| Systemic add-ons | Limited framework | Study money unclosed | No independent benefit or regimen. |
| Support and safety | NCI/NHS/provider education | Page/contributor allocations unclosed | Symptom care and referral context. |
Forms
Plasma cells normally make antibodies. NCI patient PDQ.
Solitary bone plasmacytoma
This begins in one bone, sometimes with adjacent soft-tissue extension. Vertebrae, ribs, pelvis or long bones may be involved. Adjacent extension is not automatically primary extraosseous disease. European panel 2018.
Primary extraosseous plasmacytoma
Also called extramedullary plasmacytoma, this begins in soft tissue independently of bone, often in the sinuses or throat. It differs from secondary soft-tissue spread of myeloma. Other sites include the gastrointestinal tract and lungs. European panel 2018.
Bone involvement may cause pain or fracture; soft-tissue pressure may impair swallowing. NCI patient PDQ.
Work-up
Biopsy establishes the tumor’s identity. A pathologist examines the sampled tissue and records findings in a pathology report; blood tests or an image alone cannot replace that assessment. Abnormal laboratory results do not automatically mean cancer, and normal results do not always exclude it. Ask the clinician to explain the combined findings, rather than interpreting an isolated portal result. NCI diagnosis.
Specialists evaluate marrow, serum/urine proteins, blood counts, kidney function and calcium. NCI professional PDQ.
A small marrow finding needs combined interpretation; it does not by itself establish systemic myeloma. NCI professional PDQ.
Staging combines marrow aspiration/biopsy, sensitive cell analysis and whole-body imaging. 2026 IMWG.
Local treatment
NCI lists local radiation for bone disease and radiation or selected surgery for extraosseous disease. NCI patient PDQ.
The 2018 panel described surgery for fractures, instability or compression, generally followed by radiation. European panel 2018.
External-beam treatment directs radiation from a machine at a defined area. Simulation uses imaging to map that area and position the body reproducibly. A support or head-and-neck mask may help keep the same position. Treatment-planning images guide delivery; they are not automatically a response verdict. The team explains the purpose, expected effects and consent process. NCI external beam.
Support, fatigue and complementary products
Fatigue can reflect treatment, pain, poor sleep, inadequate intake or other medical conditions. Report weakness that disrupts ordinary activities or continues despite rest. The team may investigate contributors and help plan activity and rest around your energy. A physiotherapist can assess suitable movement; a dietitian can assess intake. These are individualized support measures, not evidence that exercise or a food eradicates a plasmacytoma. NCI fatigue.
Tell the team about herbs, vitamins and other complementary products. “Natural” does not establish safety; supplements may interfere with cancer care. No special diet or supplement is established here as a cure or a way to prevent recurrence. Complementary symptom support and replacing cancer treatment are different decisions. Discuss exact products before use, including products marketed for immunity or bone health. NCI complementary care.
Uncertainty can affect work, family and day-to-day confidence. Counselors, trusted supporters or other appropriate services may help you cope with the experience. Ask for explanations in words you understand; support is appropriate even when the tumor is localized. Emotional care is valuable in its own right, without claiming it changes tumor control. NCI emotions.
Systemic treatment
Routine systemic add-ons after adequate radiation are not advised outside trials; specialist exceptions remain. 2026 IMWG.
Here, commercial ties prevent independent efficacy clearance; study finances remain unclosed.
If a clinical trial is proposed, informed consent should explain its purpose, procedures, possible benefits and harms, alternatives and the right to leave. Ask how it differs from usual care and who sponsors it. Review boards and monitoring provide safeguards; they do not guarantee an individual benefit or settle a trial’s financial independence. NCI trial safety.
Risks and urgent assessment
Call 999 in the UK, or local emergency services, for sudden arm/leg loss of feeling, inability to stand/walk, sudden loss of bladder/bowel control or acute confusion. Spinal compression is among the urgent concerns. Do not drive yourself to emergency care. Symptoms can have other causes; they still need immediate assessment. NHS neurological warnings.
Severe gasping, choking or inability to speak, marked color change or sudden confusion requires emergency help. Worsening breathlessness without those emergency signs needs urgent assessment, such as UK 111. Do not wait for a routine cancer appointment. NHS breathing warnings.
Difficulty swallowing, choking with food/drink or a wet voice after eating needs an urgent clinician/UK 111 assessment. A swallowing specialist or dietitian may be needed; food texture changes are individualized. This source is general safety information and its scheduled review is overdue. NHS swallowing.
Radiation effects depend on the field. Head-and-neck treatment may cause mouth/taste/swallowing problems; chest treatment may affect breathing; abdominal/pelvic treatment may affect bowel or urinary function. Skin changes and fatigue can occur. Some effects arise later or persist. Ask which apply to your actual field and how to report them; this is not a prediction that every listed problem will occur. NCI radiation effects.
Medicines, dental care and other coordination
Pain may arise from the tumor, a procedure or treatment effects. Describe its location, timing and impact, and report new pain, inadequate relief or medicine side effects. The care team should prescribe an individual pain plan and explain when to call. A pharmacist can help reconcile medicines; this guide supplies no safe combination list or home dose changes. NCI pain.
For treatment near the mouth, dental assessment and oral-care planning deserve attention. Mouth pain, dry mouth, infections or swallowing difficulty can compromise nutrition and hydration. Contact the cancer team when pain interferes with eating, drinking or sleeping. Inform your dentist of cancer treatment and coordinate planned dental work with the oncology team; advice depends on the treatment field and condition of the teeth. NCI mouth care.
Pregnancy and fertility planning
Tell the radiotherapy team immediately about pregnancy or possible pregnancy before planning or treatment. Leeds’ condition-specific guidance says not to start radiotherapy pregnant or become pregnant during the course. Ask the team to arrange an appropriate contraception and treatment plan; this article provides no contraception schedule or assurance for a particular field. Leeds radiotherapy.
Radiation involving reproductive organs, the pelvis or relevant hormone-controlling glands may affect male fertility. Ask about the proposed field before treatment. A cancer and fertility team can discuss preservation options such as sperm banking, their timing, cost and availability. Protection or preservation does not guarantee a future pregnancy. NCI male fertility.
For female fertility, pelvic radiation can affect ovarian function or the uterus; some effects may be lasting. Discuss fertility goals early so oncology and fertility specialists can consider appropriate options and whether any delay is acceptable. Egg, embryo or tissue preservation requires specialist assessment. It should not be arranged as a substitute for an agreed cancer plan. NCI female fertility.
Follow-up
A radiotherapy plan specifies the area treated, positioning, appointments and anticipated problems. The Leeds leaflet is a local guide; its access arrangements and schedules are not universal. Confirm your own center’s instructions, transport needs and contact route. Tell the team about previous treatment and anything that may affect planning. There is no home radiation regimen or automatic decision to interrupt treatment here. Leeds radiotherapy.
Follow-up checks for recurrence or changing disease; tests may be repeated. Report new symptoms. NCI patient PDQ.
Protein may fade slowly; healing affects scans. Persistence alone doesn't require systemic treatment. 2026 IMWG.
Animal and laboratory evidence
Laboratory mechanisms are not an individual cancer treatment plan. This article does not adopt animal or cell-culture efficacy, supplement doses, or extrapolated anti-cancer claims. A future therapy claim requires appropriate human methods, relevant outcomes and a documented financial review; an apparently independent review cannot make sponsored underlying studies independent. No personal regimen follows from the biological label “plasma cell.”
Funding and source roles
Research funding at a glance
30 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
The source-specific map separates documented institutional funding from disease-page payments and trial sponsorship. Unknown allocations remain unknown. A public agency, charity or academic address does not by itself establish independent treatment efficacy.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| European panel 2018 | Belgian Foundation against Cancer/FNRS, Deutsche Krebshilfe, AECC support; Caers reports Amgen/Celgene/Janssen honoraria and Celgene grants. | Lead Liège, Belgium; European panel | Tier 3 | C provisional; dated commercial interests, study finances unclosed. Descriptive context only. |
| IMWG 2026 | IMF support; finance. Kastritis’ disclosed ties include Janssen/Takeda consulting; institutional Janssen/Amgen/GSK grants. | Lead Athens, Greece; international panel | Tier 3 | C provisional; commercial ties, underlying study finances unclosed. |
| NCI patient PDQ | Professional derivation; board policy. | US | Tier 3 | C provisional; reviewer/service interests and study gaps. |
| NCI professional PDQ | NCI; Seifter practice, billing, declaration; policy. | US | Tier 3 | C provisional; provider interest, trial gaps. |
| Leeds radiotherapy | Provider finance; Spencer/Biesmans credited. Exact leaflet payments and current personal interests unresolved. | Leeds, UK | Tier 2 | B provisional; public provider accountability. Mixed institutional revenue, contributor gaps. |
| NCI external beam | NCI | US | Tier 2 | B provisional; mandate, contributor gaps. |
| NCI radiation effects | NCI | US | Tier 2 | B provisional; mandate, contributor gaps. |
| NCI mouth care | NCI | US | Tier 2 | B provisional; mandate, contributor gaps. |
| NCI fatigue | NCI | US | Tier 2 | B provisional; mandate, contributor gaps. |
| NCI pain | NCI | US | Tier 2 | B provisional; mandate, contributor gaps. |
| NCI diagnosis | NCI | US | Tier 2 | B provisional; mandate, contributor gaps. |
| NCI male fertility | NCI | US | Tier 2 | B provisional; mandate, contributor gaps. |
| NCI female fertility | NCI | US | Tier 2 | B provisional; mandate, contributor gaps. |
| NCI complementary care | NCI | US | Tier 2 | B provisional; mandate, contributor gaps. |
| NCI emotions | NCI | US | Tier 2 | B provisional; mandate, contributor gaps. |
| NCI trial safety | NCI | US | Tier 2 | B provisional; mandate, contributor gaps. |
| NHS myeloma symptoms | Website finance; exact contributors unclosed. | UK national website | Tier 2 | B provisional; public safety purpose, page/trial gaps. |
| NHS breathlessness | Website finance; exact contributors unclosed. | UK national website | Tier 2 | B provisional; public safety purpose, page/trial gaps. |
| NHS swallowing | Website finance; exact contributors unclosed. | UK national website | Tier 2 | B provisional; public safety purpose, page/trial gaps. |
| NHS content policy | DHSC finance; no advertising/corporate sponsorship asserted. | UK | Tier 3 | B provisional; own policy, dated 2022 and overdue review. Receipt/allocation and individual declarations unclosed. |
| NCI budget | Congressional appropriations; gifts. | US | Tier 3 | B provisional; statutory accountability, page/author allocation unclosed. |
| NCI contributions | Gift Fund/donations and stamp proceeds; specific donors/page receipts unresolved. | US; contribution address Bethesda, Maryland | Tier 3 | B provisional; own donation account. Permission or routes do not establish a page payment. |
| PDQ board policy | NCI pays nongovernment honoraria/travel; declarations and recusal, specific conflicts not published. | US; international membership | Tier 3 | B provisional; own process disclosure. Editorial autonomy does not clear finances. |
| Seifter biography | Own practice role; payment route. | Lutherville, Maryland, US | Tier 4 | D identity promotion; oncology director/Hopkins role. Equity, personal receipts and PDQ allocation unclosed. |
| Greenspring oncology | Insurance billing: BCBS/Cigna/Medicare/EHP. | US | Tier 4 | D provider self-report; service-income incentive. No medicine-company or PDQ payment inferred. |
| Seifter declaration | No disclosures/pharma-free self-statement; dated meeting. | US | Tier 3 | B provisional; bounded self-declaration, not a private-receipt audit or clearance of studies. |
| ACP meeting | Registration/member pricing; complete host income and personal honorarium unclosed. | Philadelphia, US; Maryland meeting | Tier 3 | B provisional; organizer-produced program. Education-revenue interests; exact sponsorship unclosed. |
| IMF FY2025 audit | Grants, donations, investments, events; pharmaceutical trial contracts. Three industry partners supplied about 48% educational-grant support; partners unnamed in that statement. | US California nonprofit | Tier 3 | C provisional; audited income, advocacy/industry interests. Consensus allocation and full donor chain unclosed. |
| IMF organization | Donations; formed IMWG; audited income. | Studio City, California, US headquarters; international charity | Tier 3 | C provisional; own advocacy identity. Institutional backing is not independent outcome clearance. |
| Leeds FY2025–26 accounts | NHS commissioners; private/overseas patients; research/training, services, capital donations and charitable contributions. | Leeds, UK | Tier 3 | B provisional; statutory own accounts. Industry partnerships disclosed; leaflet/person/trial allocation unclosed. |
Frequently asked questions
Is plasmacytoma myeloma? Different diagnostic scopes require systemic evaluation. NCI professional PDQ.
Will external-beam radiation make me radioactive? No. That statement is specific to external-beam treatment, not every radiation procedure. NCI external beam.
Does persistent protein require chemotherapy? Not automatically; seek specialist interpretation. 2026 IMWG.
Can swallowing problems wait until my next appointment? Seek urgent assessment; severe airway trouble is an emergency. NHS swallowing; NHS breathing warnings.
Sources and funding notes
Reviewed 5 October 2026. Bone/primary extraosseous scope; systemic myeloma separate.
Full PMC accessed; publisher PDF blocked. Selected framework/full declarations reviewed.
Older NCI outcome and routine node-field claims are excluded.
Patient PDQ derives from Seifter-led professional PDQ; funding disclosures do not clear underlying trials.
Sources concentrate in the US and UK, with an international specialist panel. Country tags describe source institutions or authors, not treatment availability, product manufacturing or a reliability ranking. Local clinicians must adapt assessment and care to their jurisdiction.
- European panel 2018 — Definition and historical surgical roles only.
- IMWG 2026 — Framework only.
- NCI patient PDQ — Local treatment/follow-up context.
- NCI professional PDQ — Selected work-up context.
- Leeds radiotherapy — Selected planning and pregnancy advice.
- NCI external beam — Planning, local delivery and radioactivity distinction.
- NCI radiation effects — Field-specific and late effects.
- NCI mouth care — Mouth, nutrition and dental assessment.
- NCI fatigue — Fatigue assessment and practical support.
- NCI pain — Individual pain assessment; no medicine regimen.
- NCI diagnosis — Pathology and test interpretation.
- NCI male fertility — Selected radiation and preservation coordination.
- NCI female fertility — Selected radiation and preservation coordination.
- NCI complementary care — Supplement/diet safety; no product efficacy.
- NCI emotions — Emotional support, not cancer treatment.
- NCI trial safety — Consent and oversight; no specific trial endorsement.
- NHS myeloma symptoms — Emergency warning context; not a diagnosis.
- NHS breathlessness — Emergency versus urgent breathing routes.
- NHS swallowing — Urgent swallowing assessment; dated source.
- NHS content policy — National website only; not Leeds finance.
- NCI budget — Institutional finance only.
- NCI contributions — Institutional gift route only.
- PDQ board policy — Board payment and disclosure limits.
- Seifter biography — Identity only; care promotion excluded.
- Greenspring oncology — Billing route only.
- Seifter declaration — Named lead declaration only.
- ACP meeting — Dates and talk identity only.
- IMF FY2025 audit — Foundation revenue only; no efficacy.
- IMF organization — Organization and HQ only.
- Leeds FY2025–26 accounts — Provider funding only.
Educational research reviewed 5 October 2026. Diagnosis and treatment require a qualified clinician; this article does not provide an individual prescription or replace urgent assessment.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.